Carregant...
Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
We evaluated the occurrence of infusion-associated reactions, severe adverse events and no evidence of disease activity 3 status of a therapeutic course consisting of natalizumab followed by alemtuzumab in paediatric-onset multiple sclerosis. Five paediatric-onset multiple sclerosis (age range 16–17...
Guardat en:
| Publicat a: | Mult Scler J Exp Transl Clin |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6747861/ https://ncbi.nlm.nih.gov/pubmed/31555463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217319875471 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|